Equities

Mankind Pharma Ltd

MANKIND:NSI

Mankind Pharma Ltd

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (INR)2,610.10
  • Today's Change56.10 / 2.20%
  • Shares traded694.43k
  • 1 Year change+36.73%
  • Beta--
Data delayed at least 15 minutes, as of Nov 25 2024 10:27 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Balance sheet Back to Overview

In millions of INR
(except for per share items)
Fiscal data as of Mar 31 2024202420232022
ASSETS
Cash And Short Term Investments33,86515,21612,943
Total Receivables, Net9,37412,18411,106
Total Inventory15,89115,30617,602
Prepaid expenses6043321,360
Other current assets, total5,9482411,056
Total current assets65,68243,27944,068
Property, plant & equipment, net31,38730,17023,896
Goodwill, net200200204
Intangibles, net16,63017,58418,742
Long term investments3,1643,6312,634
Note receivable - long term1,4601,7351,514
Other long term assets180141--
Total assets119,63397,15491,477
LIABILITIES
Accounts payable11,03010,08210,764
Accrued expenses------
Notes payable/short-term debt1,5151,1507,946
Current portion long-term debt/capital leases231270263
Other current liabilities, total8,4217,1297,262
Total current liabilities21,19718,63126,235
Total long term debt326283522
Total debt2,0721,7048,731
Deferred income tax891773556
Minority interest2,1271,8811,611
Other liabilities, total1,4611,2341,002
Total liabilities26,00222,80229,925
SHAREHOLDERS EQUITY
Common stock401401401
Additional paid-in capital421421421
Retained earnings (accumulated deficit)92,70873,41060,639
Treasury stock - common------
Unrealized gain (loss)------
Other equity, total10112091
Total equity93,63174,35261,552
Total liabilities & shareholders' equity119,63397,15491,477
Total common shares outstanding401401401
Treasury shares - common primary issue000
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.